Cystic Fibrosis
VX20-445-126
STUDY OUTLINE
The study aims to evaluate the effects of elexacaftor/tezacaftor/ivacaftor on cough and physical activity using wearable technology.
To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.
ELIGIBILITY & REQUIREMENTS
- Aged 18 or over with a diagnosis of cystic fibrosis and the F508del/MF mutation.
WHAT'S INVOLVED
- Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted.
- Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes).
PRINCIPAL INVESTIGATOR
- Dr Siobhain Mulrennan
THIS CLINICAL TRIAL IS CURRENTLY CLOSED
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.
